Compare PLNT & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLNT | LNTH |
|---|---|---|
| Founded | 1992 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 6.6B |
| IPO Year | 2015 | 2014 |
| Metric | PLNT | LNTH |
|---|---|---|
| Price | $51.19 | $100.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $107.46 | $87.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.91 |
| Revenue | ★ $1,324,144,000.00 | $343,374,000.00 |
| Revenue This Year | $19.22 | N/A |
| Revenue Next Year | $11.66 | $14.19 |
| P/E Ratio | $38.47 | ★ $34.60 |
| Revenue Growth | ★ 12.06 | 3.62 |
| 52 Week Low | $37.03 | $49.67 |
| 52 Week High | $114.26 | $111.86 |
| Indicator | PLNT | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 45.34 |
| Support Level | $49.12 | $100.51 |
| Resistance Level | $54.65 | $101.43 |
| Average True Range (ATR) | 1.62 | 0.52 |
| MACD | -0.24 | 0.10 |
| Stochastic Oscillator | 20.23 | 38.70 |
Planet Fitness Inc is a franchisor and operator of fitness centers in the United States. The company's reportable segments are Franchise, Corporate-owned stores, and Equipment. Franchise segment includes operations related to its franchising business in the United States, Puerto Rico, Canada, Panama, Mexico and Australia, Corporate-owned stores segment includes operations with respect to all corporate-owned stores throughout the United States and Canada, and The Equipment segment includes the sale of equipment to franchisee-owned stores in the U.S. The firm generates a majority of its revenue from the Corporate-owned stores segment.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.